Factors predictive of death among HIV-uninfected persons with haemophilia and other congenital coagulation disorders.
Historically, the leading cause of death among persons with haemophilia and other congenital coagulation disorders was uncontrolled bleeding. Mortality was associated with severe deficiency of coagulation factors VIII or IX and especially with high-titre antifactor neutralizing antibodies (inhibitors). The catastrophic contamination of plasma donor pools with human immunodeficiency virus (HIV) resulted in acquired immunodeficiency syndrome replacing haemorrhage as the leading cause of death among persons with haemophilia. Rather little has been written, however, about mortality among those not infected with HIV. The objective of this study was to identify conditions associated with all-cause mortality among HIV-uninfected patients who were followed for a mean of 8.8 years in the Multicentre Hemophilia Cohort Study. Among the 364 children (mean age 8 years), there were four deaths; two related to cancer, one to trauma, and the fourth to haemorrhage, end-stage liver disease and sepsis. Among the 387 HIV-uninfected adults (mean age 35 years) there were 29 deaths, with haemorrhage the leading cause of death, followed by hepatic, stroke and cancer deaths. Prognostic factors for all-cause mortality among the adults included haemophilia Type A with neutralizing antibodies [age-adjusted relative rate (RR) 3.1, 95% confidence interval (CI) 1.4-6.9] and serologic evidence of both hepatitis B and C virus (RR 4.1, 95% CI 0.97-17.6). Although hepatitis C viral load was slightly lower in patients with hepatitis B virus surface antigenaemia, it was unrelated to vital status. We conclude that causes of death and prognostic factors for current HIV-uninfected haemophilia patients are similar to those noted before the HIV epidemic. Better understanding, prevention and control of neutralizing antibodies and hepatitis infections may substantially improve longevity for people with haemophilia.
Diamondstone
L S
LS
The Research Kitchen, San Francisco, CA, USA.
Aledort
L M
LM
Goedert
J J
JJ
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001323:Autoantibodies / Q000097:blood; D001778:Blood Coagulation Disorders / Q000097:blood / Q000401:mortality* / Q000821:virology; D019774:Blood Coagulation Factor Inhibitors / Q000378:metabolism; D002423:Cause of Death; D002648:Child; D005169:Factor VIII / Q000276:immunology; D005260:Female; D018023:HIV Seronegativity; D006467:Hemophilia A / Q000097:blood / Q000401:mortality / Q000821:virology; D002836:Hemophilia B / Q000097:blood / Q000401:mortality / Q000821:virology; D006470:Hemorrhage / Q000401:mortality; D006509:Hepatitis B / Q000150:complications; D006526:Hepatitis C / Q000150:complications; D006801:Humans; D008107:Liver Diseases / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000401:mortality; D011446:Prospective Studies; D012307:Risk Factors; D020521:Stroke / Q000401:mortality; D014842:von Willebrand Diseases / Q000097:blood / Q000401:mortality / Q000821:virology
D001323:Autoantibodies; D019774:Blood Coagulation Factor Inhibitors; D005169:Factor VIII